A novel oral JAK inhibitor has shown promise in patients with rheumatoid arthritis who have failed to respond to other treatments, the results of a phase III trial show. The 24-week double blind placebo-controlled trial involved 527 patients with an inadequate response to one or more TNF inhibitors who were randomised to receive 2mg or ...
Oral JAK inhibitor promising in refractory RA
By Nicola Garrett
31 Mar 2016